Amantadine use associated with impulse control disorders in Parkinson disease in cross‐sectional study
Identifieur interne : 001C65 ( Main/Exploration ); précédent : 001C64; suivant : 001C66Amantadine use associated with impulse control disorders in Parkinson disease in cross‐sectional study
Auteurs : Daniel Weintraub [États-Unis] ; Mandy Sohr [Allemagne] ; Marc N. Potenza [États-Unis] ; Andrew D. Siderowf [États-Unis] ; Mark Stacy [États-Unis] ; Valerie Voon [Royaume-Uni] ; Jacqueline Whetteckey [États-Unis] ; Glen R. Wunderlich [Canada] ; Anthony E. Lang [Canada]Source :
- Annals of Neurology [ 0364-5134 ] ; 2010-12.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
A recent controlled clinical trial suggested a role for amantadine as a treatment for pathological gambling in patients with Parkinson disease (PD). Analyzing data from a large cross‐sectional study of impulse control disorders (ICDs) in PD, amantadine use (n = 728), vs no amantadine use (n = 2,357), was positively associated with a diagnosis of any ICD (17.6% vs 12.4%, p < 0.001) and compulsive gambling specifically (7.4% vs 4.2%, p < 0.001). This amantadine association remained after controlling for covariates of amantadine use, including both dopamine agonist use and levodopa dosage. Further research, including larger clinical trials, is needed to assess the role of amantadine in the development and treatment of ICDs in PD. Ann Neurol 2010
Url:
DOI: 10.1002/ana.22164
Affiliations:
- Allemagne, Canada, Royaume-Uni, États-Unis
- Angleterre, Caroline du Nord, Connecticut, Ontario, Pennsylvanie
- Toronto
- Université de Toronto
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000643
- to stream Istex, to step Curation: 000643
- to stream Istex, to step Checkpoint: 000652
- to stream Main, to step Merge: 001D79
- to stream PascalFrancis, to step Corpus: 000352
- to stream PascalFrancis, to step Curation: 000911
- to stream PascalFrancis, to step Checkpoint: 000395
- to stream Main, to step Merge: 001E85
- to stream Main, to step Curation: 001C65
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Amantadine use associated with impulse control disorders in Parkinson disease in cross‐sectional study</title><author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name></author><author><name sortKey="Sohr, Mandy" sort="Sohr, Mandy" uniqKey="Sohr M" first="Mandy" last="Sohr">Mandy Sohr</name></author><author><name sortKey="Potenza, Marc N" sort="Potenza, Marc N" uniqKey="Potenza M" first="Marc N." last="Potenza">Marc N. Potenza</name></author><author><name sortKey="Siderowf, Andrew D" sort="Siderowf, Andrew D" uniqKey="Siderowf A" first="Andrew D." last="Siderowf">Andrew D. Siderowf</name></author><author><name sortKey="Stacy, Mark" sort="Stacy, Mark" uniqKey="Stacy M" first="Mark" last="Stacy">Mark Stacy</name></author><author><name sortKey="Voon, Valerie" sort="Voon, Valerie" uniqKey="Voon V" first="Valerie" last="Voon">Valerie Voon</name></author><author><name sortKey="Whetteckey, Jacqueline" sort="Whetteckey, Jacqueline" uniqKey="Whetteckey J" first="Jacqueline" last="Whetteckey">Jacqueline Whetteckey</name></author><author><name sortKey="Wunderlich, Glen R" sort="Wunderlich, Glen R" uniqKey="Wunderlich G" first="Glen R." last="Wunderlich">Glen R. Wunderlich</name></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:2D5AEF6647EFF779EC31F7A50542FC439FE7A4DB</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/ana.22164</idno><idno type="url">https://api-v5.istex.fr/document/2D5AEF6647EFF779EC31F7A50542FC439FE7A4DB/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000643</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000643</idno><idno type="wicri:Area/Istex/Curation">000643</idno><idno type="wicri:Area/Istex/Checkpoint">000652</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000652</idno><idno type="wicri:doubleKey">0364-5134:2010:Weintraub D:amantadine:use:associated</idno><idno type="wicri:Area/Main/Merge">001D79</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:11-0060434</idno><idno type="wicri:Area/PascalFrancis/Corpus">000352</idno><idno type="wicri:Area/PascalFrancis/Curation">000911</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000395</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000395</idno><idno type="wicri:doubleKey">0364-5134:2010:Weintraub D:amantadine:use:associated</idno><idno type="wicri:Area/Main/Merge">001E85</idno><idno type="wicri:Area/Main/Curation">001C65</idno><idno type="wicri:Area/Main/Exploration">001C65</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Amantadine use associated with impulse control disorders in Parkinson disease in cross‐sectional study</title><author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia</wicri:cityArea></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia</wicri:cityArea></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Philadelphia Veterans Affairs Medical Center, Philadelphia</wicri:cityArea></affiliation><affiliation></affiliation></author><author><name sortKey="Sohr, Mandy" sort="Sohr, Mandy" uniqKey="Sohr M" first="Mandy" last="Sohr">Mandy Sohr</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim</wicri:regionArea><wicri:noRegion>Ingelheim</wicri:noRegion><wicri:noRegion>Ingelheim</wicri:noRegion></affiliation></author><author><name sortKey="Potenza, Marc N" sort="Potenza, Marc N" uniqKey="Potenza M" first="Marc N." last="Potenza">Marc N. Potenza</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Connecticut</region></placeName><wicri:cityArea>Department of Psychiatry, Yale University School of Medicine, New Haven</wicri:cityArea></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Connecticut</region></placeName><wicri:cityArea>Department of Child Study, Yale University School of Medicine, New Haven</wicri:cityArea></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Connecticut</region></placeName><wicri:cityArea>Department of Neurobiology, Yale University School of Medicine, New Haven</wicri:cityArea></affiliation></author><author><name sortKey="Siderowf, Andrew D" sort="Siderowf, Andrew D" uniqKey="Siderowf A" first="Andrew D." last="Siderowf">Andrew D. Siderowf</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia</wicri:cityArea></affiliation></author><author><name sortKey="Stacy, Mark" sort="Stacy, Mark" uniqKey="Stacy M" first="Mark" last="Stacy">Mark Stacy</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Caroline du Nord</region></placeName><wicri:cityArea>Department of Neurology, Duke University Medical Center, Durham</wicri:cityArea></affiliation></author><author><name sortKey="Voon, Valerie" sort="Voon, Valerie" uniqKey="Voon V" first="Valerie" last="Voon">Valerie Voon</name><affiliation wicri:level="2"><country>Royaume-Uni</country><placeName><region type="country">Angleterre</region></placeName><wicri:cityArea>University of Cambridge, Cambridge</wicri:cityArea></affiliation></author><author><name sortKey="Whetteckey, Jacqueline" sort="Whetteckey, Jacqueline" uniqKey="Whetteckey J" first="Jacqueline" last="Whetteckey">Jacqueline Whetteckey</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Connecticut</region></placeName><wicri:cityArea>Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield</wicri:cityArea></affiliation></author><author><name sortKey="Wunderlich, Glen R" sort="Wunderlich, Glen R" uniqKey="Wunderlich G" first="Glen R." last="Wunderlich">Glen R. Wunderlich</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Boehringer Ingelheim (Canada) Ltd., Burlington, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Neurology, University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-12">2010-12</date><biblScope unit="volume">68</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="963">963</biblScope><biblScope unit="page" to="968">968</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">2D5AEF6647EFF779EC31F7A50542FC439FE7A4DB</idno><idno type="DOI">10.1002/ana.22164</idno><idno type="ArticleID">ANA22164</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amantadine</term><term>Cross sectional study</term><term>Impulse control disorder</term><term>Nervous system diseases</term><term>Parkinson disease</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Amantadine</term><term>Etude transversale</term><term>Maladie de Parkinson</term><term>Pathologie du système nerveux</term><term>Trouble du contrôle des impulsions</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A recent controlled clinical trial suggested a role for amantadine as a treatment for pathological gambling in patients with Parkinson disease (PD). Analyzing data from a large cross‐sectional study of impulse control disorders (ICDs) in PD, amantadine use (n = 728), vs no amantadine use (n = 2,357), was positively associated with a diagnosis of any ICD (17.6% vs 12.4%, p < 0.001) and compulsive gambling specifically (7.4% vs 4.2%, p < 0.001). This amantadine association remained after controlling for covariates of amantadine use, including both dopamine agonist use and levodopa dosage. Further research, including larger clinical trials, is needed to assess the role of amantadine in the development and treatment of ICDs in PD. Ann Neurol 2010</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Canada</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Caroline du Nord</li><li>Connecticut</li><li>Ontario</li><li>Pennsylvanie</li></region><settlement><li>Toronto</li></settlement><orgName><li>Université de Toronto</li></orgName></list><tree><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name></region><name sortKey="Potenza, Marc N" sort="Potenza, Marc N" uniqKey="Potenza M" first="Marc N." last="Potenza">Marc N. Potenza</name><name sortKey="Potenza, Marc N" sort="Potenza, Marc N" uniqKey="Potenza M" first="Marc N." last="Potenza">Marc N. Potenza</name><name sortKey="Potenza, Marc N" sort="Potenza, Marc N" uniqKey="Potenza M" first="Marc N." last="Potenza">Marc N. Potenza</name><name sortKey="Siderowf, Andrew D" sort="Siderowf, Andrew D" uniqKey="Siderowf A" first="Andrew D." last="Siderowf">Andrew D. Siderowf</name><name sortKey="Stacy, Mark" sort="Stacy, Mark" uniqKey="Stacy M" first="Mark" last="Stacy">Mark Stacy</name><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name><name sortKey="Whetteckey, Jacqueline" sort="Whetteckey, Jacqueline" uniqKey="Whetteckey J" first="Jacqueline" last="Whetteckey">Jacqueline Whetteckey</name></country><country name="Allemagne"><noRegion><name sortKey="Sohr, Mandy" sort="Sohr, Mandy" uniqKey="Sohr M" first="Mandy" last="Sohr">Mandy Sohr</name></noRegion></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Voon, Valerie" sort="Voon, Valerie" uniqKey="Voon V" first="Valerie" last="Voon">Valerie Voon</name></region></country><country name="Canada"><noRegion><name sortKey="Wunderlich, Glen R" sort="Wunderlich, Glen R" uniqKey="Wunderlich G" first="Glen R." last="Wunderlich">Glen R. Wunderlich</name></noRegion><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C65 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001C65 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:2D5AEF6647EFF779EC31F7A50542FC439FE7A4DB
|texte= Amantadine use associated with impulse control disorders in Parkinson disease in cross‐sectional study
}}
| This area was generated with Dilib version V0.6.29. |  |